Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab

By Manuel Valladares Ayerbes, Rafael López López and Mercedes Salgado Fernández

Publisher: 'Oxford University Press (OUP)'

Year: 2015

DOI identifier: 10.1093/annonc/mdv233.269

OAI identifier: oai:runa.sergas.gal:20.500.11940/1478

Provided by: RUNA - Repositorio de Saúde

Journal:

Download PDF:
_{Sorry, we are unable to provide the full text but you may find it at the
following location(s):}

http://hdl.handle.net/20.500.1... (external link)